x
Filter:
Filters applied
- Reviews
Publication Date
Please choose a date range between 2006 and 2022.
Author
- Gasbarrini, Antonio7
- Armuzzi, Alessandro6
- Capurso, Gabriele6
- Marzioni, Marco6
- Savarino, Edoardo6
- Alpini, Gianfranco5
- Alvaro, Domenico5
- Danese, Silvio5
- Peyrin-Biroulet, Laurent5
- Andreone, Pietro4
- Bouché, Olivier4
- Bruno, Raffaele4
- Conte, Dario4
- Invernizzi, Pietro4
- Savarino, Vincenzo4
- Andreone, P3
- Angelico, Francesco3
- Bianchi Porro, G3
- Buecher, Bruno3
- Aghemo, Alessio2
- Alisi, Anna2
- Alvaro, D2
- Annese, Vito2
- Brunetto, M2
- Bruno, Savino2
Keyword
- Crohn's disease21
- Cirrhosis16
- Inflammatory bowel disease16
- Ulcerative colitis16
- Liver transplantation13
- Diagnosis12
- Chemotherapy11
- Colorectal cancer11
- Colonoscopy10
- HCC10
- HCV8
- IBD8
- Liver cirrhosis8
- GERD7
- Hepatocellular carcinoma7
- Endoscopy6
- HBV6
- Surgery6
- Dysplasia5
- ERCP5
- Immunosuppression5
- Pancreatic cancer5
- Portal hypertension5
- Alcoholic liver disease4
- NASH4
Reviews
297 Results
- Review Article
Application of histology-agnostic treatments in metastatic colorectal cancer
Digestive and Liver DiseaseVol. 54Issue 10p1291–1303Published online: June 11, 2022- Andrea Sartore-Bianchi
- Alberto Giuseppe Agostara
- Giorgio Patelli
- Gianluca Mauri
- Elio Gregory Pizzutilo
- Salvatore Siena
Cited in Scopus: 1Cancer treatment is increasingly focused on targeting molecular alterations identified across different tumor histologies. While some oncogenic drivers such as microsatellite instability (MSI) and NTRK fusions are actionable with the very same approach regardless of tumor type (“histology-agnostic”), others require histology-specific therapeutic adjustment (“histology-tuned”) by means of adopting specific inhibitors and ad hoc combinations. Among histology-agnostic therapies, pembrolizumab or dostarlimab demonstrated comparable activity in MSI metastatic colorectal cancer (mCRC) as in other tumors with MSI status (ORR 38% vs 40% and 36% vs 39%, respectively), while entrectinib or larotrectinib proved effective in NTRK rearranged mCRC even though less dramatically than in the overall population (ORR 20% vs 57%, and 50% vs 78%, respectively). - Review Article
Systematic Review: esophageal motility patterns in patients with eosinophilic esophagitis
Digestive and Liver DiseaseVol. 54Issue 9p1143–1152Published online: January 25, 2022- Pierfrancesco Visaggi
- Matteo Ghisa
- Brigida Barberio
- Elisa Marabotto
- Nicola de Bortoli
- Edoardo Savarino
Cited in Scopus: 5Eosinophilic esophagitis (EoE) is a chronic disorder of the esophagus characterized by an eosinophil-predominant inflammation and symptoms of esophageal dysfunction. Eosinophils can influence esophageal motility, leading to dysphagia worsening. The spectrum of esophageal motility in EoE is uncertain. - Review Article
Sarcopenia in chronic advanced liver diseases: A sex-oriented analysis of the literature
Digestive and Liver DiseaseVol. 54Issue 8p997–1006Published online: November 14, 2021- Maria Guarino
- Valentina Cossiga
- Chiara Becchetti
- Federica Invernizzi
- Lucia Lapenna
- Bruna Lavezzo
- and others
Cited in Scopus: 0Sarcopenia, defined as progressive and generalized loss of muscle mass and strength, is common in chronic liver disease. It significantly impacts the quality of life and increases the risk of liver-related complications and mortality in cirrhotic patients. Moreover, recent studies showed a negative impact of sarcopenia on patients awaiting liver transplantation (LT), on post-LT outcomes, and on response to hepatocellular carcinoma therapies. Data about the influence of sex on the incidence, prevalence, diagnosis and treatment of sarcopenia in chronic liver diseases are poor and conflicting. - Review Article
Exposed endoscopic full-thickness resection without laparoscopic assistance for gastric submucosal tumors: A systematic review and pooled analysis
Digestive and Liver DiseaseVol. 54Issue 6p729–736Published online: October 12, 2021- Antonino Granata
- Alberto Martino
- Dario Ligresti
- Fabio Tuzzolino
- Giovanni Lombardi
- Mario Traina
Cited in Scopus: 3Exposed endoscopic full-thickness resection (Eo-EFTR) is emerging as a promising minimally invasive alternative to surgery for the treatment of deep gastric submucosal tumors (G-SMTs). However, literature concerning this subject is heterogeneous and data mostly come from relatively small retrospective studies. - Review Article
Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective
Digestive and Liver DiseaseVol. 54Issue 5p583–597Published online: September 8, 2021- Giuseppe Losurdo
- Antonietta Gerarda Gravina
- Luca Maroni
- Enrico Maria Gabrieletto
- Gianluca Ianiro
- Alberto Ferrarese
- and others
Cited in Scopus: 1Gastroenterology, Digestive Endoscopy and Hepatology have faced significant improvements in terms of diagnosis and therapy in the last decades. However, many fields still remain poorly explored, and many questions unanswered. Moreover, basic-science, as well as translational and clinical discoveries, together with technology advancement will determine further steps toward a better, refined care for many gastroenterological disorders in the future. Therefore, the Young Investigators of the Italian Society of Gastroenterology (SIGE) joined together, offering a perspective on major future innovations in some hot clinical topics in Gastroenterology, Endoscopy, and Hepatology, as well as the current pitfalls and the grey zones. - Review Article
FAPI PET/CT research progress in digestive system tumours
Digestive and Liver DiseaseVol. 54Issue 2p164–169Published online: August 4, 2021- Dengsai Peng
- Jing He
- Hanxiang Liu
- Jianpeng Cao
- Yingwei Wang
- Yue Chen
Cited in Scopus: 818F-fluorodeoxyglucose positron emission tomography/computed tomography has been used in clinical practice for many years. This modality is of great value for tumour diagnosis, staging, and efficacy evaluations, but it has many limitations in the diagnosis and treatment of digestive system tumours. Fibroblast activation protein is highly expressed in gastrointestinal tumours. Various isotope-labelled fibroblast activation protein inhibitors are widely used in clinical research. These inhibitors have low background uptake in the brain, liver and oral/pharyngeal mucosa and show good contrast between the tumour and background, which makes up for the lack of fluorodeoxyglucose in the diagnosis of digestive system tumours. - Review Article
Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma
Digestive and Liver DiseaseVol. 54Issue 5p598–613Published online: August 2, 2021- Hui Li
Cited in Scopus: 8Intercellular crosstalk among various liver cells plays an important role in liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Capillarization of liver sinusoidal endothelial cells (LSECs) precedes fibrosis and accumulating evidence suggests that the crosstalk between LSECs and other liver cells is critical in the development and progression of liver fibrosis. LSECs dysfunction, a key event in the progression from fibrosis to cirrhosis, and subsequently obstruction of hepatic sinuses and increased intrahepatic vascular resistance (IHVR) contribute to development of portal hypertension (PHT) and cirrhosis. - Review Article
Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease
Digestive and Liver DiseaseVol. 54Issue 2p154–163Published online: July 20, 2021- Luca Valenti
- Federica Pedica
- Massimo Colombo
Cited in Scopus: 4Hepatocellular carcinoma (HCC) is on the rise globally, causing more than 800 thousand deaths annually, with an estimated annual percent change of 0.51 for causes other than viral hepatitis, including nonalcoholic fatty liver disease (NAFLD). The incidence of NAFLD-related HCC is peaking in several Far East regions (6–12% vs. 2–3% in Western Europe and USA), HCC risk being mainly driven by the epidemic of obesity and diabetes, both favored by an unhealthy diet and sedentary lifestyle. Under inherited susceptibility outlined by such genetic markers as variants in PNPLA3, TM6SF2 and MBOAT7, neoplastic transformation of NAFLD is driven by sublethal lipotoxicity consequent to hepatocyte lipid overload, whereas a myriad of factors spanning from subverted circadian homeostasis and gut dysbiosis to alcohol abuse and tobacco may interact as risk modifiers. - Review Article
Cutting edge issues in juvenile sclerosing cholangitis
Digestive and Liver DiseaseVol. 54Issue 4p417–427Published online: July 18, 2021- Angelo Di Giorgio
- Diego Vergani
- Giorgina Mieli-Vergani
Cited in Scopus: 2Sclerosing cholangitis (SC) is a rare chronic disorder characterised by inflammation and progressive obliterative fibrosis of the intrahepatic and/or extrahepatic bile ducts. Diagnosis is based on cholangiogram showing bile duct dilatation, narrowing and obliteration of the biliary tree, and histologically, on the presence of inflammatory bile duct damage leading to periductal fibrosis. In children the most common SC is associated with strong autoimmune features, overlapping with those of autoimmune hepatitis (AIH); this form is known as autoimmune sclerosing cholangitis, ASC. - Review
The application of artificial intelligence in hepatology: A systematic review
Digestive and Liver DiseaseVol. 54Issue 3p299–308Published online: July 12, 2021- Clara Balsano
- Anna Alisi
- Maurizia R. Brunetto
- Pietro Invernizzi
- Patrizia Burra
- Fabio Piscaglia
- and others
Cited in Scopus: 4The integration of human and artificial intelligence (AI) in medicine has only recently begun but it has already become obvious that intelligent systems can dramatically improve the management of liver diseases. Big data made it possible to envisage transformative developments of the use of AI for diagnosing, predicting prognosis and treating liver diseases, but there is still a lot of work to do. If we want to achieve the 21st century digital revolution, there is an urgent need for specific national and international rules, and to adhere to bioethical parameters when collecting data. - Review Article
A reasoned approach to the treatment of autoimmune hepatitis
Digestive and Liver DiseaseVol. 53Issue 11p1381–1393Published online: June 21, 2021- Diego Vergani
- Benedetta Terziroli Beretta-Piccoli
- Giorgina Mieli-Vergani
Cited in Scopus: 3Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease affecting all ages, characterised by elevated transaminase and immunoglobulin G levels, positive autoantibodies, interface hepatitis on histology and good response to immunosuppressive treatment. If untreated, it has a poor prognosis. The aim of this review is to analyse AIH therapeutic interventions with reference to our knowledge of the pathogenesis of AIH. Standard treatment, based on steroids and azathioprine, leads to disease remission in 80–90% of patients. - Review Article
Female reproductive health and inflammatory bowel disease: A practice-based review
Digestive and Liver DiseaseVol. 54Issue 1p19–29Published online: June 11, 2021- The Italian Group for the Study of Inflammatory Bowel Disease Working Group:
- Alessandro Armuzzi
- Aurora Bortoli
- Fabiana Castiglione
- Antonella Contaldo
- Marco Daperno
- and others
Cited in Scopus: 2Inflammatory bowel diseases, namely ulcerative colitis and Crohn's disease, occur worldwide and affect people of all ages, with a high impact on their quality of life. Sex differences in incidence and prevalence have been reported, and there are also gender-specific issues that physicians should recognize. For women, there are multiple, important concerns regarding issues of body image and sexuality, menstruation, contraception, fertility, pregnancy, breastfeeding and menopause. This practice-based review focuses on the main themes that run through the life of women with inflammatory bowel diseases from puberty to menopause. - Review ArticleOpen Access
Vaccinations in patients with inflammatory bowel disease
Digestive and Liver DiseaseVol. 53Issue 12p1539–1545Published online: June 8, 2021- Fabio Salvatore Macaluso
- Giuseppina Liguori
- Massimo Galli
Cited in Scopus: 8Treatment of inflammatory bowel disease (IBD) frequently requires administration of immunosuppressive therapies, which increases susceptibility to a number of infectious pathogens. However, many infections can be prevented by correct and appropriate utilization of vaccinations. While several guidelines have been published on vaccination schedules in patients with IBD, vaccination rates remain suboptimal and even lower than those in the general population. This is due to many factors including poor awareness of the importance of vaccines by gastroenterologists and general practitioners as well as potential prejudices of patients regarding the safety and benefits of vaccines. - Review Article
Treatment of primary sclerosing cholangitis
Digestive and Liver DiseaseVol. 53Issue 12p1531–1538Published online: May 16, 2021- Annarosa Floreani
- Sara De Martin
Cited in Scopus: 7Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive fibro-stenotic strictures and destruction of the biliary tree. Currently, there is no effective treatment which can delay its progression or ameliorate the transplant-free survival. Moreover, a major chontroversy in PSC is whether to use UDCA. More recently, novel pharmacological agents emerged aiming at: i) modulation of bile composition; ii) immunomodulation; iii) targeting the gut microbiome; iv) targeting fibrosis. - Review Article
Clinical usefulness of esophageal high resolution manometry and adjunctive tests: An update
Digestive and Liver DiseaseVol. 53Issue 11p1373–1380Published online: May 11, 2021- C. Prakash Gyawali
- Roberto Penagini
Cited in Scopus: 0High resolution manometry (HRM), developed from conventional manometry, is the gold standard for assessment of esophageal motor function worldwide. The Chicago Classification, now in its fourth iteration, is the modern standard for HRM categorization of esophageal motility disorders. The HRM protocol has expanded from the original 10 supine swallow standard, to include upright swallows, and provocative maneuvers such as multiple rapid swallows, rapid drink challenge and standardized test meal. Impedance has been incorporated into HRM for visualization of bolus clearance. - Review Article
Vaccinations and inflammatory bowel disease – a systematic review
Digestive and Liver DiseaseVol. 53Issue 9p1079–1088Published online: May 11, 2021- Webber Chan
- Ennaliza Salazar
- Teong Guan Lim
- Wan Chee Ong
- Hang Hock Shim
Cited in Scopus: 9Patients with inflammatory bowel disease(IBD) are at risk of infections, many of which are preventable with vaccinations. We performed a systematic review on various aspects of vaccination in IBD. - Review Article
Gastritis: The clinico-pathological spectrum
Digestive and Liver DiseaseVol. 53Issue 10p1237–1246Published online: March 28, 2021- Massimo Rugge
- Edoardo Savarino
- Marta Sbaraglia
- Ludovica Bricca
- Peter Malfertheiner
Cited in Scopus: 13The inflammatory spectrum of gastric diseases includes different clinico-pathological entities, the etiology of which was recently established in the international Kyoto classification. A diagnosis of gastritis combines the information resulting form the gross examination (endoscopy) and histology (microscopy). It is important to consider the anatomical/functional heterogeneity of the gastric mucosa when obtaining representative mucosal biopsy samples. Gastritis includes self-limiting and non-self-limiting (long-standing) inflammatory diseases, and the latter are epidemiologically, biologically and clinically linked to the onset of gastric cancer (i.e. - Review ArticleOpen Access
Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review
Digestive and Liver DiseaseVol. 53Issue 7p803–808Published online: March 17, 2021- Alessandro Armuzzi
- Giuseppina Liguori
Cited in Scopus: 18As a chronic inflammatory disease, ulcerative colitis has significant negative impact on the quality of life (QoL) of patients. Since the disease affects many aspects of QoL, comprising multiple domains, treatments that induce and maintain remission can provide benefits beyond hard clinical endpoints. Effective treatment of ulcerative colitis can restore QoL and return it to normal or near normal levels. Biological therapies have shown consistent improvement in the QoL of patients with ulcerative colitis during the induction phase, with benefits that are generally maintained in the long-term. - Review Article
Histopathology of non-IBD colitis practical recommendations from pathologists of IG-IBD Group
Digestive and Liver DiseaseVol. 53Issue 8p950–957Published online: March 9, 2021- Luca Reggiani Bonetti
- Giuseppe Leoncini
- Marco Daperno
- Maria Beatrice Principi
- Carla Baronchelli
- Stefania Manenti
- and others
Cited in Scopus: 1Pathologists are often called upon to diagnose colitides that differ from the two main forms of inflammatory bowel disease (IBD). These non-IBD colitides include infectious colitis, microscopic colitis, ischemic colitis, eosinophilic colitis, autoimmune enterocolitis, segmental colitis associated with diverticulosis, drug-induced colitis, radiation colitis and diversion colitis. The diagnosis of these different disease entities relies on the histopathological examination of endoscopic biopsies of the gastrointestinal tract. - Review Article
Gastrointestinal endoscopy in children and adults: How do they differ?
Digestive and Liver DiseaseVol. 53Issue 6p697–705Published online: March 7, 2021- Sara Isoldi
- Salvatore Cucchiara
- Alessandro Repici
- Diana G. Lerner
- Mike Thomson
- Salvatore Oliva
Cited in Scopus: 3Gastrointestinal endoscopy has grown dramatically over the past century, and with subsequent improvements in technology and anaesthesia, it has become a safe and useful tool for evaluation of GI pathology in children. There are substantial differences between paediatric and adult endoscopy beyond size, including: age-related patho-physiology and the different spectrum of diseases in children. Literature on endoscopic procedures in children is sparse but significant. The present review aims at describing the current knowledges on paediatric endoscopy practice and highlights the main areas of differences between paediatric and adult practice. - Review Article
Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know
Digestive and Liver DiseaseVol. 53Issue 6p691–696Published online: February 6, 2021- Lucas Guillo
- Ferdinando D'Amico
- Hamza Achit
- Carole Ayav
- Francis Guillemin
- Silvio Danese
- and others
Cited in Scopus: 5The kidney function monitoring is recommended in routine practice to detect 5-aminosalicylic acid (5-ASA) related nephrotoxicity, although is not standardized. The optimal monitoring is unknown, especially the best timing and which tests to perform. We summarized why, how, and when to perform the monitoring for patients treated with 5-ASA and provided an overview of the current guidelines on this topic. - Review Article
Inflammatory bowel diseases and the risk of adverse health outcomes: Umbrella review of meta-analyses of observational studies
Digestive and Liver DiseaseVol. 53Issue 7p809–816Published online: February 4, 2021- Xiaoding Shen
- Qianyi Wan
- Rui Zhao
- Yutao Wu
- Yong Wang
- Yaping Cui
- and others
Cited in Scopus: 7Accumulating evidence indicates a plausible association between inflammatory bowel diseases and the risk of adverse health outcomes. However, the conclusions are inconsistent. We aimed to perform an umbrella review of meta-analyses to appraise and grade the evidence of the association between inflammatory bowel diseases and the risk of adverse health outcomes. - Review Article
From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies
Digestive and Liver DiseaseVol. 53Issue 5p558–565Published online: February 1, 2021- Massimo Claudio Fantini
- Ilaria Guadagni
Cited in Scopus: 27The risk of colorectal cancer (CRC) is higher in patients with inflammatory bowel disease (IBD). Population-based data from patients with ulcerative colitis (UC) estimate that the risk of CRC is approximately 2- to 3-fold that of the general population; patients with Crohn's disease appear to have a similar increased risk. However, the true extent of colitis-associated cancer (CAC) in undertreated IBD is unclear. Data suggest that the size (i.e., severity and extent) and persistence of the inflammatory process is largely responsible for the development of CRC in IBD. - Review Article
Systematic assessment of environmental factors for gastroesophageal reflux disease: An umbrella review of systematic reviews and meta-analyses
Digestive and Liver DiseaseVol. 53Issue 5p566–573Published online: December 15, 2020- Yuan Cheng
- Fushun Kou
- Jiali Liu
- Yi Dai
- Xiaohong Li
- Junxiang Li
Cited in Scopus: 4Side effects of long-term acid suppression have increased the scholars’ interest in nonpharmacologic intervention. - Review Article
IBDs and the pediatric age: Their peculiarities and the involvement of the microbiota
Digestive and Liver DiseaseVol. 53Issue 1p17–25Published online: November 11, 2020- Lucia Cococcioni
- Simona Panelli
- Ilaria Varotto-Boccazzi
- Domenico Di Carlo
- Dario Pistone
- Gabriella Leccese
- and others
Cited in Scopus: 4Inflammatory Bowel Diseases (IBDs) are gastrointestinal disorders characterized by chronic, relapsing inflammation, with growing incidence worldwide over the last decades and distinctive features in the pediatric age. An increasing body of evidence indicates that gut microbiota plays a major role in inflammatory disorders, including IBDs. In this review we will discuss the most recent evidences on dysbiotic changes associated with gut inflammation, as well as environmental and genetic factors contributing to IBD pathogenesis, with a focus on the peculiarities of the pediatric age. - Review Article
Current status of systemic therapy in hepatocellular cancer
Digestive and Liver DiseaseVol. 53Issue 4p397–402Published online: October 21, 2020- Shahid Ahmed
- Lexis Gordon
- Dorie-Anna Dueck
- Osama Souied
- Kamal Haider
Cited in Scopus: 2Hepatocellular cancer (HCC) is a common cancer and an important cause of cancer-related death globally. Although surgery is the primary curative treatment, most patients at diagnosis are not surgical candidates and are treated with liver-directed therapy and or systemic therapy. Over the past decade, the systemic treatment options for patients with advanced HCC have evolved. This paper reviews recent progress in systemic therapy and the results of major clinical trials involving novel compounds in patients with HCC. - Review Article
Medical therapy versus surgery in moderate-to-severe ulcerative colitis
Digestive and Liver DiseaseVol. 53Issue 4p403–408Published online: October 10, 2020- Gionata Fiorino
- Silvio Danese
- Giovanni Giacobazzi
- Antonino Spinelli
Cited in Scopus: 4Ulcerative colitis, a chronic inflammatory condition that affects the colon from rectum to caecum, is characterized by periods of increased bowel movements, blood in feces, rectal urgency, tenesmus, and abdominal pain, with periods of remission and flares of disease, which negatively impact quality of life. A number of therapeutic options are available for patients with moderate-to-severe ulcerative colitis, however, no clear treatment algorithm exists. Therapeutic goals include short-term benefits for patients (i.e., the reduction/absence of symptoms, essentially stool frequency and rectal bleeding) and long-term benefits (i.e., sustained clinical remission, steroid-free remission, and mucosal healing). - Review Article
Update on gastroenteropancreatic neuroendocrine tumors
Digestive and Liver DiseaseVol. 53Issue 2p171–182Published online: September 7, 2020- Valentina Andreasi
- Stefano Partelli
- Francesca Muffatti
- Marco F. Manzoni
- Gabriele Capurso
- Massimo Falconi
Cited in Scopus: 18The incidence gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has dramatically risen over the last three decades, probably due to the increased detection of asymptomatic lesions. The diagnostic work-up for patients with suspected GEP-NENs is based on conventional imaging, endoscopy, pathology, and functional imaging, including 68Gallium-DOTATATE PET and 18F-FDG PET. The choice of the best treatment strategy should be based on the evaluation of tumor-related features and patient's characteristics. - Review Article
Regenerative hepatology: In the quest for a modern prometheus?
Digestive and Liver DiseaseVol. 52Issue 10p1106–1114Published online: August 29, 2020- Margarita Papatheodoridi
- Giuseppe Mazza
- Massimo Pinzani
Cited in Scopus: 2As liver-related morbidity and mortality is rising worldwide and orthotopic liver transplantation (OLT) remains the only standard-of-care for end-stage liver disease or acute liver failure, shortage of donor organs is becoming more prominent. Importantly, advances in regenerative Hepatology and liver bioengineering are bringing new hope to the possibility of restoring impaired hepatic functionality in the presence of acute or chronic liver failure. Hepatocyte transplantation and artificial liver-support systems were the first strategies used in regenerative hepatology but have presented various types of efficiency limitations restricting their widespread use. - Commentary
Addressing long-term PPI safety
Digestive and Liver DiseaseVol. 52Issue 8p853–856Published online: June 26, 2020- Carmelo Scarpignato
- Salvatore Tolone
Cited in Scopus: 3The advent of antisecretory drugs, such H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs), has revolutionized the management of acid-related diseases, leading to the virtual abolition of elective surgery for ulcer disease and relegating anti-reflux surgery to patients with reflux disease not adequately managed by medical therapy. PPIs remain the mainstay of medical treatment for gastro-esophageal reflux disease (GERD) [1–3]. They act indirectly by reducing the amount and concentration of gastric secretion available for reflux, thus lessening the aggressive power of the refluxed material [4]. - Review ArticleOpen Access
Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice
Digestive and Liver DiseaseVol. 52Issue 11p1259–1265Published online: June 26, 2020- Alessandro Armuzzi
- Yoram Bouhnik
- Fraser Cummings
- Marion Bettey
- Burkhard Pieper
- Taegyun Kang
Cited in Scopus: 6Anti-tumour necrosis factor (TNF) agents such as infliximab and adalimumab have greatly altered the treatment landscape in inflammatory bowel disease (IBD). However, there are remaining unmet needs and opportunities to optimise their use. Recent data suggest that proactive therapeutic drug monitoring may lead to more efficient usage of these agents, with potential for higher rates of corticosteroid-free clinical remission than with reactive monitoring. Expanded application of faecal calprotectin measurements may also be valuable, given the ease of use of the assay and its proven effectiveness as a diagnostic tool and predictor of relapse risk. - Review Article
Safety of probiotics in humans: A dark side revealed?
Digestive and Liver DiseaseVol. 52Issue 9p981–985Published online: June 18, 2020- Fabio Pace
- Federico Macchini
- Valeriano Massimo Castagna
Cited in Scopus: 4The term probiotic (i.e. “for life”, from the Latin and Greek words pro and bios) is relatively new, being officially introduced in 1953 by the German physician Werner Kollath [1] to designate “active substances that are essential for a healthy development of life”, though its modern definition is closer to Parker's (1974) “organisms and substances which contribute to intestinal microbial balance” [2]. In 2001 WHO/FAO proposed “live microorganisms which when administered in adequate amounts confer a health benefit on the host” [3], definition substantially left unchanged by The International Scientific Association for Probiotics and Prebiotics (ISAPP) in 2014 [4]. - Review Article
Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators
Digestive and Liver DiseaseVol. 53Issue 1p26–34Published online: June 13, 2020- Maria Arconzo
- Elena Piccinin
- Antonio Moschetta
Cited in Scopus: 7Non-alcoholic fatty liver disease (NAFLD) is a global condition characterized by an accumulation of lipids in the hepatocytes. NAFLD ranges from simple steatosis, a reversible and relatively benign condition, to fibrosis with non-alcoholic steatohepatitis (NASH), potentially leading to cirrhosis and hepatocarcinoma. NAFLD can increase the susceptibility to severe liver injury with eventual acute liver failure induced by specific hepatotoxic drugs, including acetaminophen (APAP), which is commonly used as analgesic and antipyretic. - Review Article
What gastroenterologists should know about direct oral anticoagulants
Digestive and Liver DiseaseVol. 52Issue 10p1115–1125Published online: June 9, 2020- F. Radaelli
- L. Fuccio
- S. Paggi
- C. Del Bono
- J.M. Dumonceau
- F. Dentali
Cited in Scopus: 6Direct oral anticoagulants are being increasingly used in patients with non-valvular atrial fibrillation and venous thromboembolism, due to their improved efficacy/ safety ratio, a predictable anticoagulant effect without need for routine coagulation monitoring, and fewer food and drug interactions compared with vitamin K antagonists. Gastrointestinal bleeding remains a serious complication, whose management is challenging for gastroenterologists due to the lack of a standardized clinical approach. - Review Article
Latest insights into the hot question of proton pump inhibitor safety – a narrative review
Digestive and Liver DiseaseVol. 52Issue 8p842–852Published online: June 6, 2020- Vincenzo Savarino
- Elisa Marabotto
- Manuele Furnari
- Fabiana Zingone
- Patrizia Zentilin
- Edoardo Savarino
Cited in Scopus: 20Proton pump inhibitors (PPIs) are among the most widely prescribed medications worldwide and their use is continuously increasing. Although they have been shown to combine high therapeutic efficacy and good safety profile in many studies, in last years we have witnessed the publication of many articles reporting the possible association of long-term PPI therapy with important unexpected adverse events and these observations have created alarmism in both patients and physicians. However, the majority of these studies are observational, retrospective and prone to residual confounding. - Review Article
A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring
Digestive and Liver DiseaseVol. 52Issue 9p966–980Published online: June 5, 2020- Edoardo Savarino
- Marzio Frazzoni
- Elisa Marabotto
- Patrizia Zentilin
- Paola Iovino
- Mario Costantini
- and others
Cited in Scopus: 14Patients with esophageal symptoms potentially associated with gastroesophageal reflux disease such as heartburn, regurgitation, chest pain, or cough represent one of the most frequent reasons for referral to gastroenterological evaluation. The utility of esophageal reflux monitoring in clinical practice is: (1) to accurately define reflux burden, (2) to segregate patients according to reflux monitoring results as true GERD, reflux hypersensitivity and functional heartburn, and (3) to establish a treatment plan. - Review Article
Apnea in preterm neonates: what's the role of gastroesophageal reflux? A systematic review
Digestive and Liver DiseaseVol. 52Issue 7p723–729Published online: May 15, 2020- Paolo Quitadamo
- Valentina Giorgio
- Letizia Zenzeri
- Mariella Baldassarre
- Francesco Cresi
- Osvaldo Borrelli
- and others
Cited in Scopus: 2A causal relationship between gastro-esophageal reflux (GER) and apnea in preterm infants has been frequently hypothesized and is currently debated. The present study aims at reviewing the currently available scientific evidence, in order to clarify the role of GER on the occurrence of apnea and to help improving the clinical management of apneic preterm neonates. We performed a systematic literature search to identify all the clinical studies on preterm neonates that properly assessed the relationship between apnea and GER. - Review Article
The coeliac stomach: A review of the literature
Digestive and Liver DiseaseVol. 52Issue 6p615–624Published online: April 12, 2020- Ilaria Marsilio
- Gemma Maddalo
- Matteo Ghisa
- Edoardo Vincenzo Savarino
- Fabio Farinati
- Fabiana Zingone
Cited in Scopus: 4Beyond the small intestine, coeliac disease (CeD) may affect other gastrointestinal tracts, including the stomach. However, various studies have reported conflicting results regarding the association between CeD and gastric manifestations. The aim of this study was to analyze the existing literature on gastric involvement in CeD. A literature search was conducted in bibliographic databases of Embase, PubMed, Scopus, and Web of Science. Studies reporting the association between CeD and gastric disorders were examined in detail and are fully described in the review. - Review Article
Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist
Digestive and Liver DiseaseVol. 52Issue 4p368–373Published online: February 11, 2020- Francesca Carubbi
- Maria Domenica Cappellini
- Silvia Fargion
- Anna Ludovica Fracanzani
- Fabio Nascimbeni
Cited in Scopus: 10Gaucher disease (GD), a rare lysosomal storage disorder caused by deficient glucocerebrosidase activity and consequent accumulation of glycosphingolipids in the mononuclear phagocyte system, may progress to disabling and potentially life-threatening complications when left undiagnosed and untreated. Unfortunately, because of non-specific signs and symptoms and lack of awareness, patients with type 1 GD, the most common non-neuropathic variant, frequently experience diagnostic delays. Since splenomegaly and thrombocytopenia are the dominant clinical features in many GD patients leading to first medical contact, the hepatologist and the gastroenterologist need to be aware of this condition. - Review Article
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement
Digestive and Liver DiseaseVol. 52Issue 4p359–367Published online: January 2, 2020- Fabio Nascimbeni
- Carlo Dionisi Vici
- Umberto Vespasiani Gentilucci
- Francesco Angelico
- Valerio Nobili
- Salvatore Petta
- and others
Cited in Scopus: 6Lysosomal storage diseases (LSDs) are a heterogeneous group of inherited disorders caused by loss-of-function mutations in genes encoding for lysosomal enzymes/proteins. The consequence is a progressive accumulation of substrates in these intracellular organelles, resulting in cellular and tissue damage. The overall incidence is about 1/8000 live births, but is likely underestimated. LSDs are chronic progressive multi-systemic disorders, generally presenting with visceromegaly, and involvement of the central nervous system, eyes, the skeleton, and the respiratory and cardiovascular systems. - Review Article
Understanding short bowel syndrome: Current status and future perspectives
Digestive and Liver DiseaseVol. 52Issue 3p253–261Published online: December 28, 2019- Sara Massironi
- Federica Cavalcoli
- Emanuele Rausa
- Pietro Invernizzi
- Marco Braga
- Maurizio Vecchi
Cited in Scopus: 49Short bowel syndrome (SBS) is a rare malabsorptive disorder as a result of the loss of bowel mass mostly secondary to surgical resection of the small intestine. Other causes are vascular diseases, neoplasms or inflammatory bowel disease. The spectrum of the disease is widely variable from single micronutrient malabsorption to complete intestinal failure, depending on the remaining length of the small intestine, the anatomical portion of intestine and the function of the remnant bowel. Over the last years, the management of affected patients has remarkably improved with the increase in patients’ quality of life and survival, mainly thanks to advances in home-based parenteral nutrition (PN). - Review Article
Pediatric liver diseases and ocular changes: What hepatologists and ophthalmologists should know and share with each other
Digestive and Liver DiseaseVol. 52Issue 1p1–8Published online: December 13, 2019- Livio Vitiello
- Maddalena De Bernardo
- Salvatore Guercio Nuzio
- Claudia Mandato
- Nicola Rosa
- Pietro Vajro
Cited in Scopus: 15Several rare pediatric liver disorders are accompanied by ophthalmic signs whose awareness and early identification may be of value in confirming/accelerating their diagnosis. Many of these signs are asymptomatic and can only be detected with an ophthalmological examination. Corneal signs are described in patients with Wilson’s disease, Alagille’s syndrome and some liver storage diseases. Cataract plays an important role to diagnose galactosemia. Retinal involvement is seen in some peroxisomal disorders (e.g. - Review Article
Esophageal perforation in eosinophilic esophagitis: A systematic review on clinical presentation, management and outcomes
Digestive and Liver DiseaseVol. 52Issue 3p245–252Published online: December 10, 2019- Laura Arias-González
- Esther Rey-Iborra
- Miriam Ruiz-Ponce
- Emilio J. Laserna-Mendieta
- Ángel Arias
- Alfredo J. Lucendo
Cited in Scopus: 18There is evidence of an increased fragility in the inflamed esophagus of patients with eosinophilic esophagitis (EoE). We performed a systematic review on presentation, management and outcomes of and surgical interventions for esophageal perforation in these patients, by searching in the MEDLINE, Embase and Scopus databases. Of the 599 references identified, 41 full-papers and 9 abstract met the inclusion criteria. Overall, 76 esophageal perforation episodes in 70 individual patients aged between 9 and 65 years were reported. - Review Article
Therapeutic options for coeliac disease: What else beyond gluten-free diet?
Digestive and Liver DiseaseVol. 52Issue 2p130–137Published online: December 10, 2019- Giacomo Caio
- Rachele Ciccocioppo
- Giorgio Zoli
- Roberto De Giorgio
- Umberto Volta
Cited in Scopus: 24Coeliac disease is a chronic and systemic autoimmune condition triggered by gluten ingestion in genetically predisposed subjects. Currently, the only effective treatment available is a strict, lifelong gluten-free diet. However, patients perceive gluten withdrawal as an unsustainable burden in their life and some of them can exhibit persistent symptoms despite a strict diet. Thus, gluten-free diet represents a challenge, leading scientists to look for alternative or complementary treatments. This review will focus on non-dietary therapies for coeliac disease highlighting six therapeutic strategies: (1) decreasing gluten immunogenic content before it reaches the intestine; (2) sequestering gluten in the gut lumen before absorption; (3) blocking the passage of gluten through a leaky intestinal barrier; (4) preventing the enhancement of immune response against gliadin; (5) dampening the downstream immune activation; (6) inducing immune tolerance to gluten. - Review Article
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group
Digestive and Liver DiseaseVol. 52Issue 2p138–142Published online: December 4, 2019- Ferdinando D’Amico
- Lieven Pouillon
- Marjorie Argollo
- Ailsa Hart
- Gionata Fiorino
- Elena Vegni
- and others
Cited in Scopus: 20The high cost of biological drugs for patients with inflammatory bowel disease (IBD) considerably impacts on health-care budgets. Since the patent of biological products expired, cheaper biosimilars have entered the market. Available data coming from real-world cohorts and clinical trials indicate that the efficacy and safety of biosimilars is comparable to that of the originator drugs. Treating IBD patients with a biosimilar may be complicated by the risk of the nocebo effect, a negative effect of a pharmacological or non-pharmacological treatment, induced by patients’s expectations and unrelated to the physiological action of the treatment. - Review Article
Impact of intestinal ultrasound on the management of patients with inflammatory bowel disease: how to apply scientific evidence to clinical practice
Digestive and Liver DiseaseVol. 52Issue 1p9–18Published online: November 12, 2019- Mirella Fraquelli
- Fabiana Castiglione
- Emma Calabrese
- Giovanni Maconi
Cited in Scopus: 23Technological improvements and growing sonographers’ expertise boost the role of intestinal ultrasound (IUS) in assessing patients with inflammatory bowel diseases (IBD). Non-invasiveness, low cost and good reproducibility make IUS attractive. Leveraging on the Authors’ long-term field experience, this review focuses on the IUS role in IBD patients’ clinical management. For detecting IBD, particularly Crohn’s disease, the IUS parameters — above all the evidence of a thickened bowel wall (BWT) — show very good diagnostic accuracy similar to that of MRI or CT scan. - Meta-Analysis
Chromoendoscopy or white light endoscopy for neoplasia detection in Lynch syndrome, a meta-analysis
Digestive and Liver DiseaseVol. 51Issue 11p1515–1521Published online: September 13, 2019- Ofir Har-Noy
- Diana E. Yung
- Anastasios Koulaouzidis
- Rami Eliakim
- Uri Kopylov
- Benjamin Avidan
- and others
Cited in Scopus: 4Lynch syndrome carries an increased risk of colorectal neoplasia, hence annual surveillance colonoscopy is recommended. This study aimed to compare the diagnostic yields of image enhancement modalities for colorectal neoplasia in patients with Lynch syndrome. - Review Article
Gut microbiota, dysbiosis and colon lavage
Digestive and Liver DiseaseVol. 51Issue 9p1209–1213Published online: July 27, 2019- Lorenzo Drago
- Casini Valentina
- Pace Fabio
Cited in Scopus: 20Gut microbial dysbiosis is considered an alteration of diversity and abundance of intestinal microbes, which contributes to the onset of many disorders. Several factors cause dysbiosis, depending on life-style (nutrition, stress, environment, smoking, physical activity) or particular diseases (inflammatory, autoimmune, chronic diseases). Drugs (i.e. antibiotics, anticancer drugs), as well as medical and surgical procedures, can often cause dysbiosis. Mechanical bowel preparations (MBP) and the so called "bowel cleansing" have an immediate impact on intestinal microbial composition. - Guidelines
Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
Digestive and Liver DiseaseVol. 51Issue 10p1357–1363Published online: July 15, 2019- Jean Marc Phelip
- David Tougeron
- David Léonard
- Leonor Benhaim
- Grégoire Desolneux
- Aurélien Dupré
- and others
Cited in Scopus: 63This document is a summary of the French intergroup guidelines regarding the management of metastatic colorectal cancer (mCRC) published in January 2019, and available on the French Society of Gastroenterology website (SNFGE) ( www.tncd.org ). - Review Article
Hepatotoxicity of immune check point inhibitors: Approach and management
Digestive and Liver DiseaseVol. 51Issue 8p1074–1078Published online: July 8, 2019- Ana Lleo
- Lorenza Rimassa
- Massimo Colombo
Cited in Scopus: 18Therapeutic reversal of immune tolerance following immune checkpoint inhibitors (ICPI) administration, has proven effective in prolonging survival of patients with a variety of solid and liquid tumors, often however at the expenses of discrete toxicities known as immune-related adverse events (AEs). Such reactions result from activation of the immune system and often present with generalized symptoms including fatigue or fever and, in some patients, may cause organ-specific damage. Skin, gut, endocrine, lung and musculoskeletal are the most frequent targets of ICPI toxicity whereas, cardiovascular, hematologic, renal, neurologic and ophthalmologic AEs occur much less frequently.